CA-ATOMWISE
18.12.2020 12:02:07 CET | Business Wire | Press release
Atomwise , the leader in using artificial intelligence (AI) for small-molecule drug discovery, announced today a partnership with FutuRx , a recognized Israeli-based biotechnology incubator focused on innovative, early-stage therapeutic technologies. The collaboration will serve as the first introduction of Atomwise’s AtomNet® platform for AI-based drug discovery to a growing biotech innovation hub in Israel and is Atomwise’s second partnership with a global incubator hub.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201218005044/en/
As part of the strategic partnership, Atomwise will work closely with the FutuRx management team, investors and incubated portfolio companies to apply its AI technology to early-stage drug discovery projects. Atomwise and FutuRx have announced their first joint venture, A2i Therapeutics, with seed funding to leverage Atomwise’s AI platform to target a key protein involved in controlling the innate immune response and potentially a key immuno-oncology target. Atomwise’s AI platform, AtomNet®, can screen more than 16 billion compounds for potential hits in less than two days and has been used by researchers around the world to find hits on targets across numerous disease applications.
“FutuRx is excited to launch a new bio convergence company jointly with a world leader in AI-based drug discovery,” said Kinneret Savitzky, PhD, Chief Executive Officer of FutuRx. “Atomwise brings a legacy of collaboration and innovation in small-molecule drug discovery to our network of leading experts from multinational pharmaceutical companies and venture capital, “We are happy that our partnership with Atomwise will introduce its innovative AI platform for drug discovery to startups and emerging biotech companies in Israel.”
“The Israeli Innovation Authority leads Israel’s Bio-convergence strategy and is happy to have FutuRx once again join this effort together with its new partner Atomwise,” said Anya Eldan, VP of the Innovation Authority and Head of Startup Division. “Atomwise is at the forefront of AI-driven drug discovery, and this partnership with FutuRx will help pursue difficult disease targets and significantly boost the Israeli AI drug discovery and bio-convergence ecosystem.”
FutuRx now joins Atomwise’s growing network of investor and corporate partnerships, which today represents a collective deal value approaching $7 billion. Since its founding, Atomwise has built a strong portfolio of joint-venture companies and partnerships with emerging biotechnology, leading pharmaceutical and agrochemical companies.
In April 2020, Atomwise expanded its strategic partnership with Hansoh Pharma , a leading biopharmaceutical company in China, after successfully completing their first hit-discovery collaboration to identify hit compounds that are specific towards an intractable drug target. This announcement came on the heels of another expanded partnership earlier this year with Bayer to continue the development of two crop protection programs. As part of the strategic partnership, Atomwise is helping Bayer increase the speed and probability of discovering and developing new crop protection products through AI.
“We are excited to see Atomwise, a Leaps by Bayer portfolio company, collaborating with FutuRx on new frontiers for addressing our shared goal of curing and preventing cancer,” said Dr. Juergen Eckhardt, Head of Leaps by Bayer.
About FutuRx
FutuRx is the leading biotechnology incubator in Israel, established in 2014 by Johnson & Johnson Innovation (JJDC, Inc.), OrbiMed Israel Partners, and Takeda Pharmaceutical Company, through its venture group Takeda Ventures Inc., after winning a tender of the Israeli Innovation Authority. Recently Bayer has joined FutuRx as a strategic investor through its corporate venture LEAPS. The incubator is focused on innovative, early stage therapeutic technologies, and has established 23 companies to date. For more information about FutuRx, please visit https://www.futurx.co.il .
About Atomwise
Atomwise is revolutionizing how drugs are discovered with AI. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets across 775 collaborations spanning more than 250 partners around the world. Our portfolio of joint ventures and partnerships with leading pharmaceutical, agrochemical, and emerging biotechnology companies represents a collective deal value approaching $7 billion. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster. Learn more at atomwise.com or follow @AtomwiseInc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201218005044/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems18.9.2026 07:00:00 CEST | Press release
2026 Awardees are Corus International,Humanity & Inclusion Handicap International, Kwame Nkrumah University of Science and Technology (KNUST) and Terre des hommes Foundation (Tdh)Commitment of USD 22.2 Million Increases Takeda’s Total Global CSR Program Contributions to USD 260.9 Million Across 42 Diverse Collaborations Worldwide, With 20 Currently Ongoing in 42 Countries Takeda (TSE:4502/NYSE: TAK) announced that it has awarded a total of USD 22.2 million to four new Global Corporate Social Responsibility (CSR) partners as part of the company’s ongoing commitment to supporting climate-resilient health systems in low- and middle-income countries around the world and aligned with the company’s purpose of better health for people, brighter future for the world. As climate change, extreme weather events and shifting global aid priorities continue to challenge healthcare access, Takeda is advancing its 2026 collaborations with the goal of expanding equitable access, strengthening health sy
Beacon Acquires Haize Labs to Power AI for the Real Economy17.9.2026 16:30:00 CEST | Press release
Haize Labs leadership will anchor Beacon’s new applied AI research group, accelerating the deployment of AI across the essential businesses Beacon owns Beacon Software (Beacon), the first centralized AI holding company, today announced that it has acquired Haize Labs, an AI reliability company that tests and safeguards AI agents for real-world deployment. The Haize Labs team will join Beacon to form its Applied AI Research Group, with co-founder and CEO Leonard Tang joining as VP of AI Research to lead the AI operating system that is deployed across Beacon’s companies. Beacon believes that the fastest way to bring AI to the traditional economy is through the software businesses that essential industries already use and trust, equipping them with AI infrastructure. Beacon acquires these businesses for long-term growth and connects them to a centralized AI operating system that compounds with each additional acquisition and industry. The addition of the Haize Labs team will strengthen th
TIMELAB Develops OEM/ODM Hair Straightener Reaching 200°C at All Three Measured Points in 15 Seconds17.9.2026 16:00:00 CEST | Press release
Testing at 230 V with a 260°C setting confirmed at least 200°C after 15 seconds at all three measured plate locations (front, center and rear), not just a single point. TIMELAB Co., Ltd., a Japanese beauty-appliance OEM/ODM provider, has developed a hair straightener for OEM/ODM customization for international hair care brands and professional markets. In testing at 230 V with a 260°C setting, all three measured plate locations reached at least 200°C after 15 seconds. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914187865/en/ Three-Point Plate Testing A European-market development unit with a maximum setting of 260°C was tested at 230 V. Fifteen seconds after power-on, readings at the front, center and rear were 212.5°C, 227.5°C and 200.0°C, respectively. From around 60 seconds onward, temperature differences among the three points narrowed, indicating a stable trend. Precision Temperature Control An NTC sensor inside t
Earnix Brings Agentic AI to the Decisions That Drive Insurance Performance17.9.2026 15:09:00 CEST | Press release
Agent Hub, part of Earnix AIOS, brings more than 25, insurance-specific agents and apps into Earnix’s governed pricing, underwriting, and customer decision solutions- improving workflows and business performance Earnix today announced the introduction of Agent Hub, a curated catalog of insurance-specific AI agents and apps within Earnix AIOS — the AI Orchestration System powering Earnix’s pricing and rating, underwriting, and customer engagement solutions. Agent Hub brings agentic AI directly into these solutions, enabling more intelligent workflows and strengthening the high-stakes decisions that shape pricing, underwriting, customer engagement, growth, and profitability. In an increasingly turbulent insurance environment, the useful life of an insurance decision is getting shorter. Risk and market conditions are changing faster, making growth, profitability, and portfolio performance harder to manage. AI is increasing the speed and scope of what insurers can analyze, recommend, and i
Medisca Launches Global Peptide Division17.9.2026 15:07:00 CEST | Press release
New division brings API-grade peptides and Medisca’s quality-first pharmaceutical expertise to a rapidly evolving area of personalized medicine Medisca today announced the launch of Medisca Peptides, a dedicated global division focused on expanding access to API-grade peptides and building an integrated peptide platform for pharmaceutical and personalized medicine markets worldwide. As the peptide landscape evolves, Medisca is proactively building the capabilities and infrastructure needed to support API-grade peptides within applicable regulatory frameworks. The launch represents a significant long-term commitment to peptides, including the expansion of Medisca’s portfolio, strategic manufacturing relationships, and the pharmaceutical infrastructure needed to support the category’s growth. It also signals Medisca’s ambition to become a leading force in the next generation of peptide innovation. For Medisca, the opportunity is familiar. More than 35 years ago, the company was founded t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom